A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

by | Oct 15, 2025 | Clinical Trials | 0 comments

​ Conditions: Bladder Cancer; Squamous Cell Carcinoma of the Lung; Esophageal Squamous Cell Carcinoma; Tongue Squamous Cell Carcinoma; Cutaneous Squamous Cell Cancer; Penile Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; Vulvar Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma

Interventions: Drug: EVOLVE104; Drug: EVOLVE104

Sponsors: EvolveImmune United, Inc

Recruiting Conditions: Bladder Cancer; Squamous Cell Carcinoma of the Lung; Esophageal Squamous Cell Carcinoma; Tongue Squamous Cell Carcinoma; Cutaneous Squamous Cell Cancer; Penile Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; Vulvar Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma
Interventions: Drug: EVOLVE104; Drug: EVOLVE104
Sponsors: EvolveImmune United, Inc
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *